Peptide blockers of Kv1.3 channels in T cells as therapeutics for autoimmune disease

George Kanianthara Chandy, Raymond S. Norton

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

The voltage-gated Kv1.3 channel in T lymphocytes is a validated therapeutic target for diverse autoimmune diseases. Here we review the discovery of Kv1.3, its physiological role in T cells, and why it is an attractive target for modulating autoimmune responses. We focus on peptide inhibitors because the first Kv1.3-selective inhibitor in human trials is a peptide derived from a marine organism. Two broad classes of peptides block Kv1.3, the first from scorpions and the second from sea anemones. We describe their structures, their binding site in the external vestibule of Kv1.3, how they have been engineered to improve Kv1.3-specificity, and their pharmacokinetic and pharmacodynamic properties. Finally, we highlight the therapeutic potential of Kv1.3 peptide inhibitors to treat autoimmune diseases without compromising protective immune responses.

Original languageEnglish
Pages (from-to)97-107
Number of pages11
JournalCurrent Opinion in Chemical Biology
Volume38
DOIs
Publication statusPublished - 1 Jun 2017

Cite this

@article{3d6eb08c41c04d6ea0562fa0eab3f074,
title = "Peptide blockers of Kv1.3 channels in T cells as therapeutics for autoimmune disease",
abstract = "The voltage-gated Kv1.3 channel in T lymphocytes is a validated therapeutic target for diverse autoimmune diseases. Here we review the discovery of Kv1.3, its physiological role in T cells, and why it is an attractive target for modulating autoimmune responses. We focus on peptide inhibitors because the first Kv1.3-selective inhibitor in human trials is a peptide derived from a marine organism. Two broad classes of peptides block Kv1.3, the first from scorpions and the second from sea anemones. We describe their structures, their binding site in the external vestibule of Kv1.3, how they have been engineered to improve Kv1.3-specificity, and their pharmacokinetic and pharmacodynamic properties. Finally, we highlight the therapeutic potential of Kv1.3 peptide inhibitors to treat autoimmune diseases without compromising protective immune responses.",
author = "Chandy, {George Kanianthara} and Norton, {Raymond S.}",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.cbpa.2017.02.015",
language = "English",
volume = "38",
pages = "97--107",
journal = "Current Opinion in Chemical Biology",
issn = "1367-5931",
publisher = "Elsevier",

}

Peptide blockers of Kv1.3 channels in T cells as therapeutics for autoimmune disease. / Chandy, George Kanianthara; Norton, Raymond S.

In: Current Opinion in Chemical Biology, Vol. 38, 01.06.2017, p. 97-107.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Peptide blockers of Kv1.3 channels in T cells as therapeutics for autoimmune disease

AU - Chandy, George Kanianthara

AU - Norton, Raymond S.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - The voltage-gated Kv1.3 channel in T lymphocytes is a validated therapeutic target for diverse autoimmune diseases. Here we review the discovery of Kv1.3, its physiological role in T cells, and why it is an attractive target for modulating autoimmune responses. We focus on peptide inhibitors because the first Kv1.3-selective inhibitor in human trials is a peptide derived from a marine organism. Two broad classes of peptides block Kv1.3, the first from scorpions and the second from sea anemones. We describe their structures, their binding site in the external vestibule of Kv1.3, how they have been engineered to improve Kv1.3-specificity, and their pharmacokinetic and pharmacodynamic properties. Finally, we highlight the therapeutic potential of Kv1.3 peptide inhibitors to treat autoimmune diseases without compromising protective immune responses.

AB - The voltage-gated Kv1.3 channel in T lymphocytes is a validated therapeutic target for diverse autoimmune diseases. Here we review the discovery of Kv1.3, its physiological role in T cells, and why it is an attractive target for modulating autoimmune responses. We focus on peptide inhibitors because the first Kv1.3-selective inhibitor in human trials is a peptide derived from a marine organism. Two broad classes of peptides block Kv1.3, the first from scorpions and the second from sea anemones. We describe their structures, their binding site in the external vestibule of Kv1.3, how they have been engineered to improve Kv1.3-specificity, and their pharmacokinetic and pharmacodynamic properties. Finally, we highlight the therapeutic potential of Kv1.3 peptide inhibitors to treat autoimmune diseases without compromising protective immune responses.

UR - http://www.scopus.com/inward/record.url?scp=85017438120&partnerID=8YFLogxK

U2 - 10.1016/j.cbpa.2017.02.015

DO - 10.1016/j.cbpa.2017.02.015

M3 - Review Article

VL - 38

SP - 97

EP - 107

JO - Current Opinion in Chemical Biology

JF - Current Opinion in Chemical Biology

SN - 1367-5931

ER -